Also, the role of antibodies in the recognition of cancer-specific mutated proteins such as KRAS (255) as well as CMV- and EBV-derived epitopes in the TME (259) and carbohydrates (183) cannot be dismissed and warrant deeper insights in clinical studies examining the role of TIBs in immune-recognition and immunomodulation in the tumor. The gene discussed is KRAS; the disease is neoplasm.